MOSCOW (MRC) -- Evonik resumed full operation at its 10 plants and four offices in China, said the company.
Since its outbreak, Evonik has been closely monitoring situation. In order to protect our employees and ensure safe operations, we are taking various measures according to the national and local disease control requirements.
All 10 plants and 4 offices of Evonik China have resumed full operation on February 10. Meanwhile, we are pulling together the global procurement and supply chain resources of the Evonik Group to support the production of our customers and partners. The whole business team of Evonik is ready to assist you in any emergent order for disease control purposes, seeking every possibility of fast delivery in line with local policies. It is our responsibility to provide professional, high-quality services to every customer and partner, anytime and anywhere.
Fighting against epidemic demands immediate action. In the past few weeks, many of our customers and partners were among the first movers to make donations and efforts to help control the spread of nCoV. Deeply impressed and inspired by them, Evonik also made our own contributions to the battle against nCoV through joint donation and free supply of raw materials urgently needed on the frontline.
Up to now, zero case of nCoV infection has been reported neither in Evonik China nor in other regions Evonik operates. We are doing everything within our power to keep the record. At the very beginning of the outbreak, Evonik China has assembled a regional emergency response team to guide the disease control work and the implementation of the production and operation plan. Our business teams maintain close contact with our customers and partners to fulfill their needs promptly. Our function teams are joining forces in employee communication, PPE procurement and distribution, supplier emergency management, etc. to protect our employees and operations, while at the same time to reduce the impacts to our customers and partners to the minimum.
As MRC informed earlier, Evonik joined with other manufacturers in the High Phthalates Panel (HPP), a sector group of the American Chemistry Council (ACC), in a voluntary manufacturer request to the US Environmental Protection Agency (EPA) to conduct a broad-based risk evaluation of the uses of DINP. The EPA granted the request in early December 2019, a decision welcomed by Evonik. The EPA’s risk evaluation will be performed using the best available science and weight of scientific evidence. The process will be documented and open for public review and comment.
As per MRC's ScanPlast, Russia's overall production of polyvinyl chloride (PVC) reached 975,000 tonnes in 2019, up by 2% year on year. At the same time, not all Russian producers raised their output. December total production of unmixed PVC was about 81,400 tonnes versus 84,600 tonnes a month earlier, RusVinyl decreased their capacity utilisation in November. Overall PVC production reached 975,000 tonnes in January-December 2019, compared to 958,600 tonnes a year earlier. All plants raised their output, except for Kaustik Volgograd.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of €13.3 billion and an operating profit (adjusted EBITDA) of €2.15 billion from continuing operations.
Evonik regards China as one of the driving forces of the global economy and we consequently endeavor to grow our business here. The company now employs over 2,500 employees and has in total of 10 production sites in China.
MRC